1. Home
  2. NCMI vs BWAY Comparison

NCMI vs BWAY Comparison

Compare NCMI & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National CineMedia Inc.

NCMI

National CineMedia Inc.

N/A

Current Price

$3.39

Market Cap

414.7M

ML Signal

N/A

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

N/A

Current Price

$12.71

Market Cap

450.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NCMI
BWAY
Founded
2005
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Advertising
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
414.7M
450.8M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
NCMI
BWAY
Price
$3.39
$12.71
Analyst Decision
Buy
Strong Buy
Analyst Count
5
2
Target Price
$5.90
$13.25
AVG Volume (30 Days)
548.2K
89.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
3.38%
N/A
EPS Growth
52.17
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.13
$314.08
Revenue Next Year
$7.28
$23.37
P/E Ratio
N/A
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$3.17
$7.84
52 Week High
$6.18
$26.63

Technical Indicators

Market Signals
Indicator
NCMI
BWAY
Relative Strength Index (RSI) 42.74 24.75
Support Level $3.17 $11.44
Resistance Level $3.96 $13.63
Average True Range (ATR) 0.19 1.15
MACD 0.02 -1.40
Stochastic Oscillator 30.23 7.28

Price Performance

Historical Comparison
NCMI
BWAY

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: